- Abstract viewed - 122 times
- PDF downloaded - 67 times
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright
© Medicine and Pharmacy Reports, 2024
Affiliations
Raluca Andrada Munteanu
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Cristian Silviu Moldovan
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Adrian Bogdan Tigu
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Rares Drula
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Richard Feder
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Lorand Magdo
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 23 Marinescu Street, Cluj-Napoca, Romania
Ancuta Jurj
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 23 Marinescu Street, Cluj-Napoca, Romania
Lajos Raduly
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 23 Marinescu Street, Cluj-Napoca, Romania
Liviuta Budisan
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 23 Marinescu Street, Cluj-Napoca, Romania
Radu Pirlog
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 23 Marinescu Street, Cluj-Napoca, Romania
Alin Moldovan
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Alina Andreea Zimta
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Cornelia Braicu
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 23 Marinescu Street, Cluj-Napoca, Romania
Alexandra Preda
Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
Vlad Munteanu
Department of Urology, The Oncology Institute "Prof Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania
Mihai Romitan
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Diana Gulei
Medfuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Marinescu 23/Louis Pasteur Street No. 4-6 400337 Cluj-Napoca Romania
Tudor Eliade Ciuleanu
Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
How to Cite
5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity
- Raluca Andrada Munteanu ,
- Cristian Silviu Moldovan ,
- Adrian Bogdan Tigu ,
- Rares Drula ,
- Richard Feder ,
- Lorand Magdo ,
- Ancuta Jurj ,
- Lajos Raduly ,
- Liviuta Budisan ,
- Radu Pirlog ,
- Alin Moldovan ,
- Alina Andreea Zimta ,
- Cornelia Braicu ,
- Alexandra Preda ,
- Vlad Munteanu ,
- Mihai Romitan ,
- Diana Gulei ,
- Tudor Eliade Ciuleanu
Abstract
Background and aims. Non-small cell lung cancer (NSCLC) treatment is challenged by late detection and limited therapeutic options. Aberrant DNA methylation, a common epigenetic alteration in NSCLC, offers new therapeutic avenues. This study aims to evaluate the combined effects of 5-Azacytidine (5- Aza), an epigenetic modifier, and ionizing radiation (IR) on NSCLC, exploring the underlying molecular mechanisms and therapeutic potential.
Methods. In this study, we examined the effects of 5-Aza combined with IR in both in vitro and in vivo models of NSCLC. Five human NSCLC cell lines were treated with 5-Aza and IR. Cell viability, colony formation, wound healing, and transwell migration assays were performed to assess treatment effects. Microarray and qPCR analyses were conducted to identify gene expression changes. Additionally, subcutaneous and orthotopic xenograft models were used to evaluate the treatment’s efficacy in vivo.
Results. Treatment with 5-Aza and IR resulted in significant reductions in cell viability, colony formation, and migration in NSCLC cell lines. Microarray analysis revealed significant changes in gene expression, including the upregulation of apoptosis-related genes and the downregulation of cell proliferation-related genes. In vivo studies demonstrated a notable reduction in tumor growth and metastasis in both subcutaneous and orthotopic NSCLC models following 5-Aza and IR treatment. Histological and bioluminescent imaging confirmed the therapeutic effects of the combined treatment.
Conclusions. The combination of 5-Aza and IR shows promise as an effective treatment for NSCLC, enhancing apoptosis and reducing tumor growth through epigenetic modulation.